Zepbound vs. Wegovy Trial

Order byBest matchMost fresh

Zepbound beats Wegovy for weight loss

Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide,

· 1d · on MSN

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy

· 5h

This drug led to 50% more weight loss than Wegovy in head-to-head study

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day.

· 1d

· 23h

First head-to-head trial found Zepbound beats Wegovy for weight loss

· 1d

New study compares Wegovy and Zepbound for the first time

18h

Zepbound trims more belly fat than Wegovy, study shows

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the rival medicines.

Mounjaro helps users lose more weight than Wegovy, new trial reveals

GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress on Obesity comparing new-generation weight-loss drugs

STAT1d

Pharmalittle: We’re reading about Trump drug-pricing plan, obesity drug trial data, and more

President Trump said he would sign an executive order to base U.S. drug prices on what other countries pay — usually far less than Americans do